Hemophilia Market Sees Higher Investment in Next-Gen Biologics

The global hemophilia treatment market was estimated at USD 14.11 billion in 2024 and is projected to grow to USD 21.07 billion by 2030, representing a compound annual growth rate (CAGR) of 6.91% from 2025 to 2030. Key drivers behind this growth include approvals of gene therapies and a rich pipeline of potential treatments.

Key Market Trends & Insights

• In 2024, North America held the largest regional share at 48.62%, supported by strong disease prevalence, diagnostic infrastructure, and access to advanced therapies.
• By type of hemophilia, Hemophilia A dominated with a 2024 revenue share of 73.97%, owing to higher prevalence and greater therapeutic focus compared to Hemophilia B.
• By treatment type, the on-demand segment held the largest share in 2024 at 54.95%, reflecting management of acute bleeding episodes especially in mild to moderate cases.
• By therapy, the factor replacement therapy segment recorded the highest share at 61.07% in 2024, as it remains the standard of care for both Hemophilia A and B.
• Growth in the Asia Pacific region is expected to be the fastest, driven by rising healthcare access, awareness, and government-backed rare disease programs.

Market Size & Forecast

• 2024: USD 14.11 billion
• 2030 (projected): USD 21.07 billion
• CAGR (2025–2030): 6.91%

Regional outlook: North America is the largest market in 2024; Asia Pacific is the fastest-growing region.

Increased awareness, neonatal detection programs and government support for rare diseases are further fueling market expansion. For example, in the U.S., it’s estimated that 33,000 males live with hemophilia.

Order a free sample PDF of the Hemophilia Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

The market remains concentrated among a small number of established players who benefit from global networks, strong physician relationships and payer contracts, creating high barriers to entry for newcomers.

Leading players are actively investing in next generation therapies (gene therapy, non-factor therapies) and expanding access to underserved regions.

Key Companies List

• Takeda Pharmaceutical Company Limited
• CSL Behring
• Pfizer, Inc.
• Bayer AG
• BioMarin
• Spark Therapeutics, Inc.
• Sanofi
• Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Octapharma AG

Conclusion

In summary, the hemophilia treatment market is poised for steady growth over the coming years, anchored by traditional factor replacement therapies and increasingly driven by disruptive innovations such as gene therapies and monoclonal antibodies. North America continues to lead the market while Asia Pacific is emerging as the fastest growth region. The dominance of a few major players underscores the competitive intensity and high barrier for new entrants. As awareness rises and treatment access improves globally, the market is entering a dynamic phase where improved patient outcomes, convenience of administration and cost-effectiveness will shape the next wave of growth.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.